Ordaos
New York, US · Founded 2019 · Delaware corporation · 24 employees on LinkedIn · 4 known investors
Find your way into Ordaos
3,292 people in our graph share verified history with the Ordaos team — schools, employers, funds. One of them is your warm intro.
Javier Solterounlockedknows Matthias Denecke · together at Carnegie Mellon University (overlapped)
×6knows the team · via Stanford University
×2knows the team · via Harvard University
knows the team · via Karlsruhe Institute of Technology (KIT)
knows the team · via Berklee College of Music
knows the team · via The Rockefeller University
Ordaōs uses AI and deep learning through its Design Engine to design novel mini-proteins and protein binders such as nanobodies for drug discovery. The company serves pharmaceutical and biologics researchers, combining generative machine-learning models with wet-lab protein expression and characterization.
Founders & leadership
DL
David LongoinCo-Founder & Chief Executive OfficerDavid Longo studied rumor propagation and network analysis during his undergraduate education and previously founded a music technology startup. He holds degrees from Harvard and Stanford, and is co-founder and CEO of Ordaōs, an AI-driven protein design company serving drug discovery.
MD
Matthias DeneckeinChief Technology OfficerMatthias Denecke holds a PhD in Computer Science from Karlsruhe and has spent 15+ years building production machine-learning systems across pharmaceutical, automotive, and enterprise sectors, including roles at Pfizer (semantic search for deviation reports), Ford (embedded conversational AI), and Ordaos (founding engineer to CTO), where he led platform and ML infrastructure for protein design. His published research covers reinforcement learning, natural language processing, and protein development, with two patents from NTT Communication Science Labs.
VB
Victor BustosinVP of Pre-clinical R&DVictor Bustos is VP of Pre-clinical R&D at Ordaōs. He brings over 20 years of protein engineering experience, including leadership of high-throughput cell-free expression and biophysics platforms, work with computational protein design methods, and prior roles as a Group Leader at Rockefeller University in the laboratory of Nobel Laureate Paul Greengard where he led drug discovery in neurodegenerative diseases, as well as experience founding an Alzheimer's diagnostics startup.
SH
Scott HornerNamed on SEC filing
Board
BB
UP
Ulo PalmBoard director
JR
Investors · 4
Reported raises · per SEC filings
Form D private placements$16.8M disclosed across 6 rounds · 2022–2025
▶$337.7KraisedApr 2025 · 3 investors · BiotechnologyRule 506(b)
▶$337.7KraisedApr 2025 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ulo PalmDirector
- David LongoExecutive Officer, Director
- Benjamin BrittDirector
- James RameyDirector
- Offering amount
- $2M
- Amount sold
- $337.7K
- Minimum investment
- $25K
- First sale
- Feb 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.1MraisedSep 2024 · 5 investors · BiotechnologyRule 506(b)
▶$3.1MraisedSep 2024 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ulo PalmDirector
- James RameyDirector
- David LongoExecutive Officer, Director
- Benjamin BrittDirector
- Offering amount
- $4M
- Amount sold
- $3.1M
- Minimum investment
- $30K
- First sale
- Aug 2024
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$500KraisedDec 2023 · 2 investors · BiotechnologyRule 506(b)
▶$500KraisedDec 2023 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ulo PalmDirector
- Benjamin BrittDirector
- David LongoExecutive Officer, Director
- James RameyDirector
- Offering amount
- $500K
- Amount sold
- $500K
- First sale
- Dec 2023
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$332KraisedDec 2023 · 4 investors · BiotechnologyRule 506(b)
▶$332KraisedDec 2023 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Benjamin BrittDirector
- Ulo PalmDirector
- James RameyDirector
- David LongoExecutive Officer, Director
- Offering amount
- $1.8M
- Amount sold
- $332K
- First sale
- Dec 2023
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$1.8MraisedNov 2023 · 4 investors · BiotechnologyRule 506(b)
▶$1.8MraisedNov 2023 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James RameyDirector
- David LongoExecutive Officer, Director
- Benjamin BrittDirector
- Ulo PalmDirector
- Offering amount
- $5M
- Amount sold
- $1.8M
- First sale
- Mar 2023
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$10.7MraisedJun 2022 · 10 investors · BiotechnologyRule 506(b)
▶$10.7MraisedJun 2022 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ulo PalmDirector
- David LongoExecutive Officer, Director
- Benjamin BrittDirector
- Scott HornerDirector
- Offering amount
- $10.7M
- Amount sold
- $10.7M
- Minimum investment
- $5.4K
- First sale
- Jun 2022
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 6
by search overlap
Artios Pharma15 shared keywordsArtios develops DNA damage response (DDR)-based medicines targeting patients with high unmet need cancers. The company focuses on advancing DDR-based therapies through strategic partnerships.
Pathos10 shared keywordsPathos applies AI, biological modeling, and a large collection of multimodal oncology patient data to develop cancer drugs and accelerate clinical development. It operates the PathOS platform with engines for asset selection, clinical trial execution, and an oncology foundation model.
Kronos Bio7 shared keywords
Orca Bio6 shared keywordsOrca Bio develops allogeneic T-cell immunotherapies for high-risk blood cancers including acute myeloid leukemia, acute lymphocytic leukemia, and myelodysplastic syndrome. The company is advancing precision cell therapy treatments for patients with blood cancers and autoimmune diseases.
OS Therapies6 shared keywordsOS Therapies (OST) is a clinical-stage cancer immunotherapy company developing treatments that activate the immune system to target HER2-expressing cancers, initially focusing on osteosarcoma in children and adults. It plans to expand its lead candidate into breast, colorectal, esophageal, lung, ovarian, and pancreatic cancers and other solid tumors.
Optimeos6 shared keywordsOptimeos develops a nanoparticle-based drug formulation and delivery platform (CINCs and LINCs) for complex biologics including mRNA, DNA, peptides, and proteins, targeting rare diseases, immunology, and metabolic conditions such as obesity. Its technology enables intracellular and long-acting delivery for pharmaceutical and biotech partners addressing challenges like tissue targeting and dosing profiles.
Companies competing with Ordaos for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Ordaos do?
- Ordaōs uses AI and deep learning through its Design Engine to design novel mini-proteins and protein binders such as nanobodies for drug discovery. The company serves pharmaceutical and biologics researchers, combining generative machine-learning models with wet-lab protein expression and characterization.
- Who are Ordaos's investors?
- Ordaos's investors include Citta Capital, Route 66 Ventures, IAG Capital Partners, Middleland Capital.
- How much funding has Ordaos raised?
- Ordaos has disclosed $16.8M raised across 6 rounds.
- Where is Ordaos headquartered?
- Ordaos is headquartered in New York, US.